SCHEMBL3757863

SCHEMBL3757863

Cc1cccc(C)c1OP(=O)(OCl)OCl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.40
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GAA P10253 1/20 0.38
CYP3A4 P08684 3/20 0.37
CYP1A2 P05177 3/20 0.37
CYP2C19 P33261 1/20 0.37
TSHR P16473 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
SCN4A P35499 3/20 0.33
KMT2A Q03164 3/20 0.33
SCN1A P35498 2/20 0.33
SCN5A Q14524 2/20 0.33
SCN9A Q15858 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4990431 0.96 MAPT (0.40) MAPTLMNASMN1; SMN2GAACYP3A4
SCHEMBL940949 0.87 MAPT (0.45) MAPTLMNASMN1; SMN2GAACYP3A4
SCHEMBL28397604 0.83 MAPT (0.42) MAPTLMNASMN1; SMN2GAACYP3A4
SCHEMBL30772416 0.82 MAPT (0.39) MAPTLMNASMN1; SMN2GAACYP3A4
SCHEMBL12997457 0.81 MAPT (0.41) MAPTLMNASMN1; SMN2GAACYP3A4
SCHEMBL28055475 0.81 MAPT (0.41) MAPTLMNASMN1; SMN2GAACYP3A4
Phosphoric Acid SCHEMBL8344759 0.81 INPPL1 (0.42) MAPTLMNASMN1; SMN2GAACYP3A4
SCHEMBL27204291 0.80 INPPL1 (0.38) MAPTLMNASMN1; SMN2GAAKDM4E
SCHEMBL131318 0.79 CYP3A4 (0.59) MAPTLMNASMN1; SMN2GAACYP3A4
SCHEMBL3759319 0.79 CYP3A4 (0.43) CYP3A4TSHRKDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117999319-A Halogen-free flame-retardant curable resin composition, prepreg, metal-clad laminate, and printed wiring board 日铁化学材料株式会社 2024-05-07 CN disclosed
CN-117143147-A Method for efficiently synthesizing resorcinol bis [ di (2, 6-dimethylphenyl) phosphate ] 浙江万盛股份有限公司 2023-12-01 CN disclosed
CN-117024658-A Phospholipid terminal functionalized rare earth isoprene rubber and preparation method and application thereof 海南天然橡胶产业集团股份有限公司 2023-11-10 CN disclosed
CN-113912642-A Phosphorus-containing (meth) acryloyl compound, method for producing same, flame-retardant resin composition, and laminate for electronic circuit board 日铁化学材料株式会社 2022-01-11 CN disclosed
CN-113912643-A Phosphorus-containing vinylbenzyl ether compound, process for producing the same, flame-retardant resin composition, and laminate for electronic circuit board 日铁化学材料株式会社 2022-01-11 CN disclosed
US-20100298506-A1 METHOD FOR PRODUCING AN AMINO GROUP-CONTAINING PHOSPHATE COMPOUND, AND A FLAME-RETARDANT RESIN AND FLAME-RETARDANT RESIN COMPOSITION SHOWA HIGHPOLYMER CO., LTD. (JP) 2010-11-25 US disclosed
EP-2036911-A1 PROCESS FOR PRODUCTION OF AMINATED PHOSPHORIC ACID ESTER COMPOUND, FLAME-RETARDANT RESIN, AND FLAME-RETARDANT RESIN COMPOSITION SHOWA HIGHPOLYMER CO., LTD. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298506-A1 METHOD FOR PRODUCING AN AMINO GROUP-CONTAINING PHOSPHATE COMPOUND, AND A FLAME-RETARDANT RESIN AND FLAME-RETARDANT RESIN COMPOSITION ATIC, GART, RPP30 MAPT 2201/4885LMNA 3985/4885SMN1; SMN2 4067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.